• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    3/21/24 5:33:35 PM ET
    $APVO
    $BIOL
    $CUTR
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $APVO alert in real time by email

    Gainers

    • Biolase (NASDAQ:BIOL) stock rose 20.0% to $0.18 during Thursday's after-market session. The market value of their outstanding shares is at $3.4 million. As per the press release, Q4 earnings came out today.
    • Terns Pharma (NASDAQ:TERN) shares rose 10.14% to $7.21. The company's market cap stands at $466.4 million.
    • Aptevo Therapeutics (NASDAQ:APVO) stock increased by 9.37% to $4.9. The market value of their outstanding shares is at $2.6 million.
    • Nexalin Technology (NASDAQ:NXL) shares increased by 7.62% to $0.48. The company's market cap stands at $3.4 million.
    • Evolus (NASDAQ:EOLS) stock moved upwards by 7.61% to $14.84. The company's market cap stands at $912.6 million.
    • Phio Pharma (NASDAQ:PHIO) stock moved upwards by 7.52% to $0.9. The market value of their outstanding shares is at $4.1 million.

    Losers

    • Cutera (NASDAQ:CUTR) stock decreased by 11.7% to $2.03 during Thursday's after-market session. The company's market cap stands at $40.5 million. As per the press release, Q4 earnings came out today.
    • Hyperfine (NASDAQ:HYPR) stock declined by 7.97% to $1.04. The company's market cap stands at $74.4 million. As per the press release, Q4 earnings came out today.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock declined by 7.66% to $1.81. The market value of their outstanding shares is at $1.0 million.
    • Vicarious Surgical (NYSE:RBOT) stock decreased by 5.24% to $0.36. The company's market cap stands at $63.2 million.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) stock fell 5.14% to $0.79. The company's market cap stands at $19.8 million.
    • Assure Hldgs (NASDAQ:IONM) stock fell 4.81% to $0.5. The market value of their outstanding shares is at $4.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APVO
    $BIOL
    $CUTR
    $EOLS

    CompanyDatePrice TargetRatingAnalyst
    Terns Pharmaceuticals Inc.
    $TERN
    3/25/2026Buy → Neutral
    H.C. Wainwright
    Terns Pharmaceuticals Inc.
    $TERN
    2/9/2026$58.00Outperform
    Leerink Partners
    Terns Pharmaceuticals Inc.
    $TERN
    11/4/2025$20.00Neutral → Buy
    H.C. Wainwright
    Terns Pharmaceuticals Inc.
    $TERN
    11/3/2025Mkt Perform → Outperform
    William Blair
    Terns Pharmaceuticals Inc.
    $TERN
    10/15/2025$20.00Buy
    Truist
    Terns Pharmaceuticals Inc.
    $TERN
    9/17/2025$15.00Overweight
    Barclays
    Terns Pharmaceuticals Inc.
    $TERN
    9/4/2025Neutral
    H.C. Wainwright
    Evolus Inc.
    $EOLS
    8/6/2025Buy → Hold
    Needham
    More analyst ratings

    $APVO
    $BIOL
    $CUTR
    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

    A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous CarcinomasKing of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compound PH-762 for both clinical trial and commercial supply."It is a pleasure to partner with an organization known for its quality and ex

    3/30/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    How Decentralized AI is Unlocking Value in Cardiac Diagnostics

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

    3/27/26 9:30:00 AM ET
    $BEAT
    $GEHC
    $HTFL
    Medical/Dental Instruments
    Health Care
    Medical Electronics
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing

    WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the "OTCQB"). The Company's Class A common stock has begun quotation on the OTCQB as of March 24, 2026, under the ticker symbol RBOT. This milestone represents a key step in the Company's broader capital markets strategy as it advances toward a potential listing on the Nasdaq Capital Market. The OTCQB is designed for early-stage and developing companies

    3/25/26 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $APVO
    $BIOL
    $CUTR
    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Teisseyre Thomas

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    3/25/26 5:15:11 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Hale Brett

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    3/25/26 5:14:23 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Moatazedi David

    4 - Evolus, Inc. (0001570562) (Issuer)

    3/20/26 7:19:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    $BIOL
    $CUTR
    $EOLS
    SEC Filings

    View All

    Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events

    8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    3/30/26 7:15:34 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.

    SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    3/27/26 1:32:59 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Aptevo Therapeutics Inc.

    10-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

    3/26/26 4:15:24 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    $BIOL
    $CUTR
    $EOLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    $BIOL
    $CUTR
    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Terns Pharmaceuticals downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Terns Pharmaceuticals from Buy to Neutral

    3/25/26 10:23:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Terns Pharmaceuticals with a new price target

    Leerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00

    2/9/26 6:54:14 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Terns Pharmaceuticals from Neutral to Buy and set a new price target of $20.00

    11/4/25 8:12:25 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    $BIOL
    $CUTR
    $EOLS
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APVO
    $BIOL
    $CUTR
    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 7:00:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Meihua International Medical Technologies Co. Ltd.

    SC 13G - Meihua International Medical Technologies Co., Ltd. (0001835615) (Subject)

    11/14/24 6:08:55 PM ET
    $MHUA
    Medical/Dental Instruments
    Health Care

    $APVO
    $BIOL
    $CUTR
    $EOLS
    Financials

    Live finance-specific insights

    View All

    Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. F

    3/5/26 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

    Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company's Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half 2026 Net Revenue Guidance of $327 Million to $337 Million,

    3/3/26 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care